|
|
作者：丁香园肿瘤时间
本文仅供医疗卫生等专业人士参考
内容策划：唐颖
内容审核：于轩
题图来源：丁香园自制
参考文献：
[1] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 2.2024, March 11, 2024.
[2] 2024中国临床肿瘤学会(CSCO)乳腺癌诊疗指南.
[3] Bardia A, Tolaney SM, Loirat D,et al. Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Treated Metastatic Triple-Negative Breast Cancer: Final Data From the Phase 3 ASCENT Study. 2022 ASCO. P1071.
[4] Peter Schmid, et al. Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A Phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC). 2024 ESMO BC abstract 181O.
[5] Schmid P, Wysocki P, Park YH, et al; Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study. 2022 SABCS. PD11-08.
|
|
